IP Library Granted Patent US 10,323,001
Granted Patent B2
US 10,323,001 · App. 15/387,322 · Granted Jun 18, 2019

Compositions for modulating a kinase cascade and methods of use thereof

Inventors: David G. Hangauer, Jr. (Lancaster, NY); Debasis Patra (Manlius, NY); Jeremy A. Cody (Clifton Springs, NY); Grant J. Palmer (Nashville, TN); Paul K. Isbester (Castleton on Hudson, NY); Jonathon Salsbury (Madison, WI)
Assignee: Athenex, Inc.
C07D213/56C07D213/59C07D413/12A61K31/44C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,323,001
App. No.
15/387,322
Granted
Jun 18, 2019
Kind
B2
Abstract

The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.

Claims (1)

1. A topical, ointment composition comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide free base, wherein the purity of 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide free base is greater than 98.0% as determined by HPLC.

Assignments (9)
SECURITY INTEREST Recorded Sep 16, 2022
From: ATNX SPV, LLC
To: SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 061119/0920 →
SECURITY INTEREST Recorded Sep 16, 2022
From: ATHENEX, INC.
To: SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 061119/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2022
From: ATHENEX, INC.
To: ATNX SPV, LLC
Reel/Frame 061071/0086 →
SECURITY INTEREST Recorded Jun 22, 2020
From: ATHENEX, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 053005/0657 →
RELEASE OF SECURITY INTEREST Recorded Jun 19, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ATHENEX, INC.
Reel/Frame 052990/0677 →
PATENT SECURITY AGREEMENT Recorded Jul 3, 2018
From: ATHENEX, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047247/0812 →
CHANGE OF NAME Recorded Mar 23, 2017
From: KINEX PHARMACEUTICALS, INC.
To: ATHENEX, INC.
Reel/Frame 042077/0615 →
CHANGE OF NAME Recorded Feb 10, 2017
From: KINEX PHARMACEUTICALS, LLC
To: KINEX PHARMACEUTICALS, INC.
Reel/Frame 041679/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2017
From: HANGAUER, DAVID G., JR.; PATRA, DEBASIS; CODY, JEREMY A.; PALMER, GRANT J.; ISBESTER, PAUL K.; SALSBURY, JONATHON
To: KINEX PHARMACEUTICALS, LLC
Reel/Frame 041202/0597 →
Continuity (9)
Continuation 14554495 · Nov 26, 2014
Continuation 13614063 · Sep 13, 2012
Continuation 13094679 · Apr 26, 2011
Continuation 12468694 · May 19, 2009
Continuation In Part 12154056 · May 19, 2008
Continuation In Part 12005792 · Dec 28, 2007
Provisional Application 60930758 · May 17, 2007
Provisional Application 60877762 · Dec 28, 2006
Related Publication 20170101378A1 · Apr 13, 2017
Cited By (2)
US 12,215,083 US 12,667,576